JP2020533273A - 多量体ｔ細胞調節ポリペプチドおよびその使用方法 - Google Patents

多量体ｔ細胞調節ポリペプチドおよびその使用方法 Download PDF

Info

Publication number
JP2020533273A
JP2020533273A JP2020503686A JP2020503686A JP2020533273A JP 2020533273 A JP2020533273 A JP 2020533273A JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020533273 A JP2020533273 A JP 2020533273A
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
examples
immunomodulatory
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020503686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533273A5 (https=
Inventor
ロナルド ディー． ザ サード セイデル
ロナルド ディー． ザ サード セイデル
ロドルフォ ジェイ． チャパーロ
ロドルフォ ジェイ． チャパーロ
Original Assignee
キュー バイオファーマ， インコーポレイテッド
キュー バイオファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュー バイオファーマ， インコーポレイテッド, キュー バイオファーマ， インコーポレイテッド filed Critical キュー バイオファーマ， インコーポレイテッド
Publication of JP2020533273A publication Critical patent/JP2020533273A/ja
Publication of JP2020533273A5 publication Critical patent/JP2020533273A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020503686A 2017-09-07 2018-09-06 多量体ｔ細胞調節ポリペプチドおよびその使用方法 Pending JP2020533273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555499P 2017-09-07 2017-09-07
US62/555,499 2017-09-07
PCT/US2018/049756 WO2019051091A1 (en) 2017-09-07 2018-09-06 T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

Publications (2)

Publication Number Publication Date
JP2020533273A true JP2020533273A (ja) 2020-11-19
JP2020533273A5 JP2020533273A5 (https=) 2021-10-28

Family

ID=65634643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503686A Pending JP2020533273A (ja) 2017-09-07 2018-09-06 多量体ｔ細胞調節ポリペプチドおよびその使用方法

Country Status (12)

Country Link
US (4) US20200148744A1 (https=)
EP (1) EP3678691A4 (https=)
JP (1) JP2020533273A (https=)
KR (1) KR20200040860A (https=)
CN (1) CN111050793A (https=)
AU (1) AU2018328280B2 (https=)
BR (1) BR112020004535A2 (https=)
CA (1) CA3070484A1 (https=)
EA (1) EA202090471A1 (https=)
IL (2) IL272085B2 (https=)
MX (1) MX2020002596A (https=)
WO (1) WO2019051091A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP3719033A1 (en) 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
KR102440962B1 (ko) * 2020-03-18 2022-09-07 ㈜지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2021230638A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL299834A (en) * 2020-07-14 2023-03-01 Cue Biopharma Inc with binding sites and methods for using them T - cellular modulatory polypeptides
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
JP2025508958A (ja) 2022-03-01 2025-04-10 クロスリンク セラピューティクス インク． 抗癌剤としての免疫細胞機能のａｔｐ依存性アゴニスト
AU2024268752A1 (en) * 2023-05-11 2026-01-08 Immudex Aps Mhc class i molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
SG11201605632SA (en) * 2014-01-21 2016-08-30 Einstein Coll Med Cellular platform for rapid and comprehensive t-cell immunomonitoring
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOHOKU J. EXP. MED., vol. 168, JPN6022029260, 1992, pages 231 - 237, ISSN: 0005032546 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法

Also Published As

Publication number Publication date
EP3678691A4 (en) 2021-06-09
EA202090471A1 (ru) 2020-06-10
TW201920248A (zh) 2019-06-01
MX2020002596A (es) 2020-07-20
EP3678691A1 (en) 2020-07-15
WO2019051091A1 (en) 2019-03-14
CA3070484A1 (en) 2019-03-14
US20240025964A1 (en) 2024-01-25
IL272085B (en) 2022-11-01
IL297361A (en) 2022-12-01
BR112020004535A2 (pt) 2020-09-08
IL297361B1 (en) 2024-03-01
US20250002556A1 (en) 2025-01-02
CN111050793A (zh) 2020-04-21
IL272085A (en) 2020-03-31
US20200148744A1 (en) 2020-05-14
AU2018328280B2 (en) 2025-02-20
IL297361B2 (en) 2024-07-01
KR20200040860A (ko) 2020-04-20
US20220119483A1 (en) 2022-04-21
AU2018328280A1 (en) 2020-02-13
IL272085B2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
JP2020533273A (ja) 多量体ｔ細胞調節ポリペプチドおよびその使用方法
JP7295325B2 (ja) ヘテロ二量体、ホモ二量体及び医薬組成物
US11702461B2 (en) T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides
JP2021500855A (ja) 抗原提示ポリペプチドおよびその使用方法
JP7691927B2 (ja) Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
JP7481342B2 (ja) 多量体ｔ細胞調節ポリペプチド及びその使用方法
JP2022515330A (ja) 多量体ｔ細胞調節ポリペプチド及びその使用方法
TWI918592B (zh) 多聚體ｔ細胞調節多肽及其使用方法
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40102809A (zh) T细胞调节性多聚体多肽及其使用方法
HK40102438A (zh) T细胞调节性多聚体多肽及其使用方法
HK40102439A (zh) T细胞调节性多聚体多肽及其使用方法
HK40102436A (zh) T细胞调节性多聚体多肽及其使用方法
HK40109852A (zh) T细胞调节性多聚体多肽及其使用方法
EA047549B1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200306

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230410